BLACK DIAMOND THERAPEUTICS, INC. Operating Expenses
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Operating Expenses of $12.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $12.06M, a 10.16% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $11.26M, a 27.22% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $17.61M, a 3.64% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $10.98M, a 39.45% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. operating expenses for fiscal 2025 was $57.48M, a 27.04% decline from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. operating expenses for fiscal 2024 was $78.78M, a 8.88% decline from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. operating expenses for fiscal 2023 was $86.46M, a 6.86% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. operating expenses for fiscal 2022 was $92.83M, a 26.83% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.06M 10-Q · filed 2026-08-05 | $23.32M 10-Q · filed 2026-08-05 | $40.93M derived: sum of 3 quarters · filed 2026-08-05 | $51.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $11.26M 10-Q · filed 2026-05-07 | $28.87M derived: sum of 2 quarters · filed 2026-05-07 | $39.85M derived: sum of 3 quarters · filed 2026-05-07 | $53.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $17.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $28.59M derived: sum of 2 quarters · filed 2026-03-16 | $42.01M derived: sum of 3 quarters · filed 2026-08-05 | $57.48M 10-K · filed 2026-03-16 |
| 2025-09-30 | $10.98M 10-Q · filed 2025-11-06 | $24.40M derived: sum of 2 quarters · filed 2026-08-05 | $39.87M 10-Q · filed 2025-11-06 | $58.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $13.42M 10-Q · filed 2026-08-05 | $28.89M 10-Q · filed 2026-08-05 | $47.16M derived: sum of 3 quarters · filed 2026-08-05 | $65.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $15.47M 10-Q · filed 2026-05-07 | $33.74M derived: sum of 2 quarters · filed 2026-05-07 | $51.88M derived: sum of 3 quarters · filed 2026-05-07 | $74.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $36.41M derived: sum of 2 quarters · filed 2026-03-16 | $58.53M derived: sum of 3 quarters · filed 2026-03-16 | $78.78M 10-K · filed 2026-03-16 |
| 2024-09-30 | $18.13M 10-Q · filed 2025-11-06 | $40.26M derived: sum of 2 quarters · filed 2025-11-06 | $60.51M 10-Q · filed 2025-11-06 | $81.36M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $22.13M 10-Q · filed 2025-08-07 | $42.38M 10-Q · filed 2025-08-07 | $63.23M derived: sum of 3 quarters · filed 2025-08-07 | $87.24M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $20.25M 10-Q · filed 2025-05-12 | $41.10M derived: sum of 2 quarters · filed 2025-05-12 | $65.11M derived: sum of 3 quarters · filed 2025-05-12 | $85.14M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $20.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $44.87M derived: sum of 2 quarters · filed 2025-03-06 | $64.90M derived: sum of 3 quarters · filed 2025-03-06 | $86.46M 10-K · filed 2025-03-06 |
| 2023-09-30 | $24.01M 10-Q · filed 2024-11-05 | $44.04M derived: sum of 2 quarters · filed 2024-11-05 | $65.61M 10-Q · filed 2024-11-05 | $87.46M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $20.03M 10-Q · filed 2024-08-06 | $41.59M 10-Q · filed 2024-08-06 | $63.45M derived: sum of 3 quarters · filed 2024-08-06 | $85.57M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $21.56M 10-Q · filed 2024-05-09 | $43.41M derived: sum of 2 quarters · filed 2024-05-09 | $65.54M derived: sum of 3 quarters · filed 2024-05-09 | $88.71M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $21.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $43.98M derived: sum of 2 quarters · filed 2024-03-12 | $67.15M derived: sum of 3 quarters · filed 2024-03-12 | $92.83M 10-K · filed 2024-03-12 |
| 2022-09-30 | $22.12M 10-Q · filed 2023-11-06 | $45.30M derived: sum of 2 quarters · filed 2023-11-06 | $70.98M 10-Q · filed 2023-11-06 | $97.06M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $23.17M 10-Q · filed 2023-08-11 | $48.85M 10-Q · filed 2023-08-11 | $74.93M derived: sum of 3 quarters · filed 2023-08-11 | $110.30M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $25.68M 10-Q · filed 2023-05-09 | $51.76M derived: sum of 2 quarters · filed 2023-05-09 | $87.12M derived: sum of 3 quarters · filed 2023-05-09 | $121.84M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $26.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $61.44M derived: sum of 2 quarters · filed 2023-03-09 | $96.16M derived: sum of 3 quarters · filed 2023-03-09 | $126.87M 10-K · filed 2023-03-09 |
| 2021-09-30 | $35.36M 10-Q · filed 2022-11-08 | $70.08M derived: sum of 2 quarters · filed 2022-11-08 | $100.79M 10-Q · filed 2022-11-08 | $123.97M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $34.72M 10-Q · filed 2022-08-09 | $65.43M 10-Q · filed 2022-08-09 | $88.61M derived: sum of 3 quarters · filed 2022-08-09 | $107.09M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $30.71M 10-Q · filed 2022-05-11 | $53.90M derived: sum of 2 quarters · filed 2022-05-11 | $72.38M derived: sum of 3 quarters · filed 2022-05-11 | $87.40M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $23.18M 10-K · filed 2021-03-25 | $41.66M derived: sum of 2 quarters · filed 2021-11-08 | $56.69M derived: sum of 3 quarters · filed 2021-11-08 | $69.57M 10-K · filed 2022-03-17 |
| 2020-09-30 | $18.48M 10-Q · filed 2021-11-08 | $33.51M derived: sum of 2 quarters · filed 2021-11-08 | $46.39M 10-Q · filed 2021-11-08 | $56.73M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $15.03M 10-Q · filed 2021-08-12 | $27.91M 10-Q · filed 2021-08-12 | $38.25M derived: sum of 3 quarters · filed 2021-08-12 | $46.40M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $12.88M 10-Q · filed 2021-05-07 | $23.22M derived: sum of 2 quarters · filed 2021-05-07 | $31.37M derived: sum of 3 quarters · filed 2021-05-07 | $38.37M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $10.34M 10-K · filed 2021-03-25 | $18.49M derived: sum of 2 quarters · filed 2021-03-25 | $25.49M derived: sum of 3 quarters · filed 2021-03-25 | $29.33M 10-K · filed 2021-03-25 |
| 2019-09-30 | $8.15M 10-K · filed 2021-03-25 | $15.15M derived: sum of 2 quarters · filed 2021-03-25 | $18.99M 10-Q · filed 2020-11-10 | $22.03M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $7.00M 10-K · filed 2021-03-25 | $10.84M 10-Q · filed 2020-08-11 | $13.89M derived: sum of 3 quarters · filed 2021-03-25 | $16.23M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $3.84M 10-K · filed 2021-03-25 | $6.89M derived: sum of 2 quarters · filed 2021-03-25 | $9.23M derived: sum of 3 quarters · filed 2021-03-25 | $11.14M derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $3.05M 10-K · filed 2020-03-24 | $5.38M derived: sum of 2 quarters · filed 2020-03-24 | $7.30M derived: sum of 3 quarters · filed 2020-03-24 | $8.90M 10-K · filed 2020-03-24 |
| 2018-09-30 | $2.34M 10-K · filed 2020-03-24 | $4.25M derived: sum of 2 quarters · filed 2020-03-24 | $5.86M derived: sum of 3 quarters · filed 2020-03-24 | |
| 2018-06-30 | $1.91M 10-K · filed 2020-03-24 | $3.52M derived: sum of 2 quarters · filed 2020-03-24 | ||
| 2018-03-31 | $1.60M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |